D epression is a serious illness. Numerous studies show that MDD is associated with significant personal distress and burden of disability. 1 The good news is that there are many effective treatments available to treat MDD. The bad news is that not everyone experiences a full response to treatment. For example, the Sequenced Treatment Alternatives to Relieve Depression (commonly known by its acronym, STAR*D) effectiveness study found that, in the real world, remission outcomes are modest, with only 33% of patients with MDD achieving full remission of symptoms after the first AD and only 67% after 1 year of treatment involving up to 4 treatment steps. 2 Thus a significant percentage of patients will have a TRD, regardless of how treatment-resistant is defined. 3 It is also clear that TRD is associated with poor outcomes and a disproportionate amount of the burden associated with MDD. 4, 5 Although TRD is often used in the literature as if it were a distinct entity, there is considerable variability in how TRD is defined and there is no consensus definition. 6 For example, a commonly applied definition for TRD is failure of 2 or more ADs, preferably from different classes. However, some studies define resistant depression as failure of one AD, while others attempt to stage resistance by incorporating responses to other treatments (including older medications, such as tricyclic ADs or monoamine oxidase inhibitors, and somatic treatments, such as electroconvulsive therapy). 7 Moreover, the definition of failure also varies considerably from study to study. Some TRD studies include patients with treatment failure by history, while others define failure prospectively. These diagnostic issues contribute to significant heterogeneity in TRD samples, which makes it difficult to compare treatment studies of TRD.
In the context of modest success rates with AD monotherapy for MDD, how can we optimize outcomes for the large proportion of patients with TRD? We practice in an evidence-based medicine climate, so it is important to first consider evidence-based treatment approaches. However, we need to remember to differentiate between evidence of lack of efficacy and lack of evidence of efficacy. The latter is much more representative of the evidence landscape in psychiatry than the former. While there is reasonable evidence to support choices for initial pharmacotherapy of MDD, there is still only limited evidence for many important clinical questions, including how to manage poor or incomplete response to an initial AD.
To further complicate the issue, the terminology for treatment strategies for TRD is changing. Augmentation and combination have been used in the literature to describe distinct strategies when adding another medication to an AD. Augmentation referred to adding a medication that was not considered an AD (for example, lithium or triiodothyronine), while combination referred to the practice of adding a second AD (for example, desipramine or bupropion). However, the definition of an AD is blurring and some medications that were considered augmentation agents may be effective ADs on their own. For example, older studies indicated that lithium may have acute AD 8 and more recent studies show that some atypical antipsychotics (for example, quetiapine extended release 9 ) are effective as monotherapy for nonpsychotic MDD. For this reason, some authors have suggested that the terms augmentation and combination be replaced by add-on or adjunctive, which do not infer the type of medication added. 10 The 2009 revision of the CANMAT depression guidelines summarizes the evidence for pharmacologic strategies for TRD. 10 CANMAT used a strict guidelines process that rated evidence according to pre-defined criteria for Level of Evidence, with the highest, Level 1, defined as at last 2 randomized controlled trials, with adequate sample size, and (or) a meta-analysis, with narrow confidence intervals. There is currently Level 1 evidence to support the use of several of the adjunctive agents for TRD, such as lithium and atypical antipsychotics.
In this issue, Dr Michael E Thase 11 provides a comprehensive and systematic review of the evidence supporting an adjunctive strategy using combination treatment with 2 ADs. As the Perspective article clearly shows, there is little evidence to support this strategy for TRD, which was listed in the CANMAT guidelines as having only Level 2 or 3 evidence. 10 Why, then, are AD combinations used so frequently in clinical practice? There are likely many reasons, but some possibilities include: 1. clinicians may be more comfortable with prescribing ADs than other more proven adjunctive strategies, 2. there are few drug-drug interactions with combination ADs, and 3. clinicians may believe that specific residual symptoms (or side effects) from the first AD can be alleviated by a specific second AD.
Again, there is currently no evidence to support this latter practice, but there is also no current evidence base to guide management of residual symptoms.
In summary, clinicians continue to struggle to find effective treatments for patients with TRD who show suboptimal response (that is, those who do not achieve full symptom remission) on AD monotherapy. There is currently good evidence to support various adjunctive treatments but still little evidence to guide when a given treatment should be used. Given the limited evidence base for combination ADs, clinicians should be cautious about using this strategy. However, pharmacotherapy remains as much of an art as it is a science, and choice of treatment still must be customized for a given patient based on their unique riskbenefit assessment.
